Author: Aseptix

CDX/MRD Coming Soon We are currently building something amazing for you. Stay tuned!

iCarbonX Pharmaceutical’s Antimicrobial Peptide Drug Candidate iCAMP016 Receives Clinical Trial Approval, Unleashing the Potential of Silicon-Based Chips + AI in Drug Discovery 2025-12-18 On December 17, 2025, iCAMP016 vaginal gel, an antimicrobial peptide Class I innovative drug…

iCarbonX Pharmaceutical Initiates Phase I Clinical Study of Antimicrobial Peptide Drug Candidate iCAMP016 On May 8, 2026, the initiation meeting for the Phase I clinical study of iCAMP016, an antimicrobial peptide drug candidate developed by iCarbonX Pharmaceutical,…

IVD Reagent Products iCarbonX IntelliCore has developed an in vitro diagnostic product portfolio based on silicon-based peptide chips and PNA chips, covering oncology, autoimmune diseases, allergies, and pathogen detection. The silicon-based chip platform offers high…

Diagnostic Instrument Portfolio iCarbonX IntelliCore has established an instrument portfolio covering both silicon-based chip and membrane chip testing, including microarray chip scanners, biochip analyzers, and automated sample loading systems. Together, these instruments support a standardized…

Health Management and Intervention Products

Where Carbon-Based Life Meets Its Silicon Future. Founded by Dr. Jun Wang in 2015 and headquartered in Shenzhen, China, iCarbonX is a pioneering Digital Life unicorn company. Leveraging artificial intelligence and silicon-based biochip technologies, iCarbonX…